- Home
- HTBI vs EYPT Comparison
HTBI vs EYPT Comparison
Compare HTBI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HTBI
- EYPT
- Stock Information
- Founded
- HTBI 1926
- EYPT 1987
- Country
- HTBI United States
- EYPT United States
- Employees
- HTBI N/A
- EYPT N/A
- Industry
- HTBI Savings Institutions
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- HTBI Finance
- EYPT Industrials
- Exchange
- HTBI Nasdaq
- EYPT Nasdaq
- Market Cap
- HTBI 641.9M
- EYPT 594.5M
- IPO Year
- HTBI 2012
- EYPT 2005
- Fundamental
- Price
- HTBI $34.23
- EYPT $7.48
- Analyst Decision
- HTBI Buy
- EYPT Strong Buy
- Analyst Count
- HTBI 4
- EYPT 8
- Target Price
- HTBI $39.00
- EYPT $25.71
- AVG Volume (30 Days)
- HTBI 31.9K
- EYPT 922.9K
- Earning Date
- HTBI 01-27-2025
- EYPT 03-06-2025
- Dividend Yield
- HTBI 1.40%
- EYPT N/A
- EPS Growth
- HTBI 14.18
- EYPT N/A
- EPS
- HTBI 3.52
- EYPT N/A
- Revenue
- HTBI $187,440,000.00
- EYPT $45,713,000.00
- Revenue This Year
- HTBI N/A
- EYPT N/A
- Revenue Next Year
- HTBI N/A
- EYPT N/A
- P/E Ratio
- HTBI $9.73
- EYPT N/A
- Revenue Growth
- HTBI 2.84
- EYPT 7.50
- 52 Week Low
- HTBI $23.55
- EYPT $6.90
- 52 Week High
- HTBI $38.99
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- HTBI 51.35
- EYPT 44.49
- Support Level
- HTBI $31.11
- EYPT $7.15
- Resistance Level
- HTBI $33.83
- EYPT $8.25
- Average True Range (ATR)
- HTBI 0.82
- EYPT 0.66
- MACD
- HTBI 0.16
- EYPT -0.01
- Stochastic Oscillator
- HTBI 99.36
- EYPT 22.01
About HTBI HomeTrust Bancshares Inc.
HomeTrust Bancshares Inc operates as a bank holding company. It engaged in the business of planning, directing and coordinating the business activities of the Bank. The Bank is a North Carolina state chartered bank and provides a range of retail and commercial banking products.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.